Changes in US stocks | First “oral weight loss elixir” approved, Novo Nordisk (NVO.US) rose more than 8% before the market

The Zhitong Finance App learned that Novo Nordisk (NVO.US) rose more than 8% to $52.29 in the premarket on Tuesday. According to the news, the US FDA approved Novo Nordisk's first oral GLP-1 diet drug, giving it a head start in competition with Eli Lilly. The oral version of Wegovy will be available in the US in early January next year, with a starting cash price of $149 per month. Clinical data shows that it can help patients lose up to 16.6% of their weight and reduce cardiovascular risk.

According to reports, Eli Lilly's own oral diet pills are expected to be approved in March next year. This means Novo Nordisk has a valuable window of several months to consolidate its initial advantage in the oral medicine market.